Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-11-21

Clinical Trial Update: An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 trial compares CNTO 1275 (ustekinumab) to etanercept to evaluate efficacy and safety in adults with plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CNTO 1275 (ustekinumab)
  • Etanercept (etanercept)

Snippet

Sponsor: Centocor, Inc. | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2012-11-21